The author discusses a study by D. Dahl and colleagues in the issue which present the findings of the SURPASS-5 clinical trial that compared three doses of the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide versus placebo in the treatment of patients with type 2 diabetes. Topics include participants excluded in the study, effectiveness of tirzepatide compared with placebo, and factors associated with the use of tirzepatide.